Cargando…
Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
We reviewed the literature to assess the efficacy and risk of constitutional, cardiac, gastrointestinal, and dermatological toxicities of combined BRAF plus MEK inhibitors versus BRAF inhibitors alone in patients with metastatic melanoma with BRAF mutations. Searches were conducted in PubMed, Cochra...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966686/ https://www.ncbi.nlm.nih.gov/pubmed/31817473 http://dx.doi.org/10.3390/cancers11121950 |
_version_ | 1783488794472742912 |
---|---|
author | Greco, Austin Safi, Danish Swami, Umang Ginader, Tim Milhem, Mohammed Zakharia, Yousef |
author_facet | Greco, Austin Safi, Danish Swami, Umang Ginader, Tim Milhem, Mohammed Zakharia, Yousef |
author_sort | Greco, Austin |
collection | PubMed |
description | We reviewed the literature to assess the efficacy and risk of constitutional, cardiac, gastrointestinal, and dermatological toxicities of combined BRAF plus MEK inhibitors versus BRAF inhibitors alone in patients with metastatic melanoma with BRAF mutations. Searches were conducted in PubMed, Cochrane Database of Systematic Reviews, Google scholar, ASCO, Scopus, and EMBASE for reports published from January 2010 through March 2019. Efficacy, including progression-free survival (PFS) and overall survival (OS) rates, were assessed by hazard ratio (HR); objective response rates (ORR) were assessed by odds ratio (OR). The randomized clinical trials (RCTs) with comparison to vemurafenib monotherapy were included to determine constitutional, gastrointestinal, cardiac, and dermatological toxicities using PRISMA statistical analysis with relative risk (RR) for equal comparison to avoid inclusion bias. Five RTCs comprising 2307 patients were included to assess efficacy, while three of the five RCTs comprising 1776 patients were included to assess adverse events. BRAF plus MEK inhibitor combination therapy demonstrated overall better efficacy compared to BRAF inhibitor monotherapy. Combination therapies appear to have favorable dermatologic side effect profiles, similar constitutional and cardiac profiles, and slightly worse gastrointestinal profiles compares to monotherapy regimens. |
format | Online Article Text |
id | pubmed-6966686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69666862020-02-04 Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review Greco, Austin Safi, Danish Swami, Umang Ginader, Tim Milhem, Mohammed Zakharia, Yousef Cancers (Basel) Review We reviewed the literature to assess the efficacy and risk of constitutional, cardiac, gastrointestinal, and dermatological toxicities of combined BRAF plus MEK inhibitors versus BRAF inhibitors alone in patients with metastatic melanoma with BRAF mutations. Searches were conducted in PubMed, Cochrane Database of Systematic Reviews, Google scholar, ASCO, Scopus, and EMBASE for reports published from January 2010 through March 2019. Efficacy, including progression-free survival (PFS) and overall survival (OS) rates, were assessed by hazard ratio (HR); objective response rates (ORR) were assessed by odds ratio (OR). The randomized clinical trials (RCTs) with comparison to vemurafenib monotherapy were included to determine constitutional, gastrointestinal, cardiac, and dermatological toxicities using PRISMA statistical analysis with relative risk (RR) for equal comparison to avoid inclusion bias. Five RTCs comprising 2307 patients were included to assess efficacy, while three of the five RCTs comprising 1776 patients were included to assess adverse events. BRAF plus MEK inhibitor combination therapy demonstrated overall better efficacy compared to BRAF inhibitor monotherapy. Combination therapies appear to have favorable dermatologic side effect profiles, similar constitutional and cardiac profiles, and slightly worse gastrointestinal profiles compares to monotherapy regimens. MDPI 2019-12-05 /pmc/articles/PMC6966686/ /pubmed/31817473 http://dx.doi.org/10.3390/cancers11121950 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Greco, Austin Safi, Danish Swami, Umang Ginader, Tim Milhem, Mohammed Zakharia, Yousef Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review |
title | Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review |
title_full | Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review |
title_fullStr | Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review |
title_full_unstemmed | Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review |
title_short | Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review |
title_sort | efficacy and adverse events in metastatic melanoma patients treated with combination braf plus mek inhibitors versus braf inhibitors: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966686/ https://www.ncbi.nlm.nih.gov/pubmed/31817473 http://dx.doi.org/10.3390/cancers11121950 |
work_keys_str_mv | AT grecoaustin efficacyandadverseeventsinmetastaticmelanomapatientstreatedwithcombinationbrafplusmekinhibitorsversusbrafinhibitorsasystematicreview AT safidanish efficacyandadverseeventsinmetastaticmelanomapatientstreatedwithcombinationbrafplusmekinhibitorsversusbrafinhibitorsasystematicreview AT swamiumang efficacyandadverseeventsinmetastaticmelanomapatientstreatedwithcombinationbrafplusmekinhibitorsversusbrafinhibitorsasystematicreview AT ginadertim efficacyandadverseeventsinmetastaticmelanomapatientstreatedwithcombinationbrafplusmekinhibitorsversusbrafinhibitorsasystematicreview AT milhemmohammed efficacyandadverseeventsinmetastaticmelanomapatientstreatedwithcombinationbrafplusmekinhibitorsversusbrafinhibitorsasystematicreview AT zakhariayousef efficacyandadverseeventsinmetastaticmelanomapatientstreatedwithcombinationbrafplusmekinhibitorsversusbrafinhibitorsasystematicreview |